Przejdź do głównej treści

Widok zawartości stron Widok zawartości stron

Ruthenium complexes – cytotoxic and antimetastatic activity

Morescheme of potential antimetastatic activity of ruthenium complexes such as inhibition of MMP-9 and MMP-2 as well as inhibition of cell detachment, invasion and migration, transmigration, re-adhesion than 90% of cancer deaths are estimated to be associated with metastases. To adapt anticancer therapy to this phenomenon, in addition to cytotoxic properties, the compound should inhibit metastasis formation at many stages of the process.

The main goal of our work is to test ruthenium complexes using various in vitro functional assays to provide information on the tested compounds' effect on cancer cells' ability to detach, migrate, invade, survive, or adhere. In addition to functional tests, molecular assays based on various markers are used to understand the molecular mechanism of activity and to identify potential targets for the tested compounds.

In cooperation with Prof. Philippe Gros and Prof. Franck Suzenet, we have designed a series of Ru polypyridyl complexes, and some of which had a pronounced impact on cancer cell detachment, migration, and adhesion as well as on endothelial cell angiogenesis (OPUS 11).

In cooperation with Dr M. Ganeshpandian (NAWA Indo-Polish project) we have tested ruthenium organometallic compounds as potential cytotoxic and antimetastatic agents.

The application of Ru polypyridyl complexes as potential photosensitizers in photodynamic therapy (PDT) is evaluated considering hypoxic conditions as well as light-induced enhancement of antimetastatic activity.